Mu Hao received her Ph.D. degree in 2007 at the Sichuan University of China and then completed her postdoc training at the University of Iowa, USA. Now, she is the Professor and Principal Investigator of the Department of State Kay Lab of Experimental Hematology, Institution of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College. She is an investigator who has focused on myeloma and related diseases for more than 15 years basically and translationally, and she has published many peer-reviewed scientific papers in this field. The main emphasis of her research is to identify the pathogenesis of multiple myeloma and other malignancies of plasma cells. Multiple myeloma is a heterogeneous disease with a complex genetic landscape, characterized by several numerical and structural aberrations. Although proteasome inhibitors (PIs) have transformed the management of multiple myeloma (MM) and improved the outcome of patients, MM is still incurable. Drug resistance remains the key problem and causes refractory states and relapses in MM. Her current interest is focused on the functional investigation of oncogenes and non-coding RNAs involved in myeloma development and drug resistance. Another interest is focused on the tumor microenvironment's interaction with tumor cells in the pathogenesis and progression of multiple myeloma.
